X hits on this document

27 views

0 shares

0 downloads

0 comments

10 / 11

Bec2/BCG Vaccination in SCLC Patients

Authors’ Disclosures of Potential Conflicts of Interest

Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Authors

Giuseppe Giaccone Paul B. Chapman

Employment

Leadership

Consultant

Stock

Honoraria Merck (A)

Research Funds

Merck (B); Imclone (B)

Testimony

Other

Oriol Masso

Merck

Dollar Amount Codes

(A) $10,000

(B) $10,000-99,999

(C) $100,000

(N/R) Not Required

REFERENCES

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005

2. Krug LM, Grant SC, Miller VA, et al: Strat- egies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Semin Oncol 26:55-61, 1999 (5 suppl 15)

3. Hanqing M, Avrova N, Mansson JE, et al: Gangliosides and neutral glycosphingolipids of normal tissue and oat cell carcinoma of human lung. Biochim Biophys Acta 878:360-370, 1986

4. Brezicka T, Bergman B, Olling S, et al: Reactivity of monoclonal antibodies with gangli- oside antigens in human small cell lung cancer tissues. Lung Cancer 28:29-36, 2000

5. Zhang S, Cordon-Cardo C, Zhang HS, et al: Selection of tumor antigens as targets for im- mune attack using immunohistochemistry: I. Fo- cus on gangliosides. Int J Cancer 73:42-49, 1997

6. Fuentes R, Allman R, Mason MD: Gangli- oside expression in lung cancer cell lines. Lung Cancer 18:21-33, 1997

7. Ritter G, Ritter-Boosfeld E, Adluri R, et al: Analysis of the antibody response to immuniza- tion with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 62:668-672, 1995

8. McCaffery M, Yao TJ, Williams L, et al: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2:679-686, 1996

9. Yao TJ, Meyers M, Livingston PO, et al: Immunization of melanoma patients with BEC2- keyhole limpet hemocyanin plus BCG intrader- mally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5:77-81, 1999

10. Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti- idiotypic antibody BEC2 plus Bacillus Calmette- Guerin. Clin Cancer Res 5:1319-1323, 1999

11. Chapman PB: Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4:710-715, 2003

12. Chapman PB, Wu D, Ragupathi G, et al: Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglio- side. Clin Cancer Res 10:4717-4723, 2004

13. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4:31-42, 1973

14. Klimek VM, Williams LJ, Holland S, et al: Bacillus Calmette-Guerin (BCG) can be used safely as an immunological adjuvant in patients with a positive PPD or a history of tuberculosis (TB). Proc Am Soc Clin Oncol 19;466a, 2000 (abstract)

15. Chapman PB, Williams L, Salibi N, et al: A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22:2904-2909, 2004

16. Turrisi AT III: Limited stage small cell lung cancer: Treatment and therapy. Curr Treat Op- tions Oncol 4:61-64, 2003

17. Turrisi AT III, Kim K, Blum R, et al: Twice- daily compared with once-daily thoracic radio- therapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999

18. Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. European Organization for Research and Treat- ment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11:1230-1240, 1993

19. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 59:584-590, 1989

20. Sculier JP, Paesmans M, Bureau G, et al: Randomized trial comparing induction chemo- therapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 14:2337-2344, 1996

21. Schiller JH, Adak S, Cella D, et al: Topote- can versus observation after cisplatin plus eto- poside in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Coopera- tive Oncology Group. J Clin Oncol 19:2114-2122, 2001

22. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-

cell carcinoma of the lung: A randomized study. J Clin Oncol 5:1864-1873, 1987

23. Leyvraz S, Perey L, Rosti G, et al: Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17: 3531-3539, 1999

24. Mattson K, Niiranen A, Ruotsalainen T, et al: Interferon maintenance therapy for small cell lung cancer: Improvement in long-term survival. J Interferon Cytokine Res 17:103-105, 1997

25. Mattson K, Niiranen A, Pyrhonen S, et al: Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 28A: 1387-1391, 1992

26. Ruotsalainen TM, Halme M, Tamminen K, et al: Concomitant chemotherapy and IFN-alpha for small cell lung cancer: A randomized multi- center phase III study. J Interferon Cytokine Res 19:253-259, 1999

27. Kelly K, Crowley JJ, Bunn PA Jr, et al: Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. J Clin Oncol 13:2924-2930, 1995

28. van Zandwijk N, Groen HJ, Postmus PE, et al: Role of recombinant interferon-gamma main- tenance in responding patients with small cell lung cancer: A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 33:1759-1766, 1997

29. Jett JR, Maksymiuk AW, Su JQ, et al: Phase III trial of recombinant interferon gamma in complete responders with small-cell lung can- cer. J Clin Oncol 12:2321-2326, 1994

30. Pujol JL, Gibney DJ, Su JQ, et al: Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. J Natl Cancer Inst 85:1844-1850, 1993

31. Shepherd FA, Giaccone G, Seymour L, et

al:

Prospective,

randomized,

double-blind,

placebo-controlled trial of marimastat after re- sponse to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002

32. Gail MH: A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0

www.jco.org

6863

Downloaded from jco.ascopubs.org on February 15, 2015. For personal use only. No other uses without permission. Copyright © 2005 American Society of Clinical Oncology. All rights reserved.

Document info
Document views27
Page views27
Page last viewedTue Dec 06 10:55:04 UTC 2016
Pages11
Paragraphs513
Words8777

Comments